Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 17
1966 29
1967 20
1968 32
1969 35
1970 33
1971 42
1972 29
1973 39
1974 44
1975 48
1976 33
1977 49
1978 61
1979 67
1980 58
1981 48
1982 75
1983 84
1984 93
1985 106
1986 109
1987 117
1988 97
1989 127
1990 104
1991 104
1992 113
1993 98
1994 105
1995 120
1996 133
1997 115
1998 115
1999 108
2000 140
2001 103
2002 115
2003 114
2004 130
2005 113
2006 157
2007 151
2008 141
2009 143
2010 168
2011 170
2012 196
2013 182
2014 193
2015 163
2016 165
2017 137
2018 127
2019 134
2020 112
2021 72
2022 51
2023 41
2024 80
2025 80
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,515 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Ann Surg Oncol. 2024 Aug;31(8):5340-5351. doi: 10.1245/s10434-024-15293-x. Epub 2024 May 4. Ann Surg Oncol. 2024. PMID: 38704501 Free PMC article. Clinical Trial.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Mateos MV, et al. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. Lancet. 2020. PMID: 31836199 Clinical Trial.
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodríguez-Otero P, Leleu X, Richardson PG. Nadeem O, et al. Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680. Drugs Today (Barc). 2022. PMID: 35983927 Review.
Optimizing high dose melphalan.
Shah G, Giralt S, Dahi P. Shah G, et al. Blood Rev. 2024 Mar;64:101162. doi: 10.1016/j.blre.2023.101162. Epub 2023 Dec 10. Blood Rev. 2024. PMID: 38097487 Review.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Lahuerta JJ, San-Miguel J, Jiménez-Ubieto A, Alonso R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernández Guijarro M, Tamayo RR, Rocafiguera AO, Blanchard MJ, Carrillo Cruz E, Martínez-Martínez R, Bargay J, Sureda Balari A, Rubia J, Hernández García MT, Cabañas V, Montero FC, Bernal LP, Montes YG, Martínez-Lopez J, Rodriguez-Otero P, Krisnik I, Arguiñano JM, Gonzalez García ME, Ocio EM, Cruz J, Mateos MV, Rosiñol L, Bladé J. Lahuerta JJ, et al. Blood. 2025 Oct 9;146(15):1747-1758. doi: 10.1182/blood.2025028313. Blood. 2025. PMID: 40499010 Clinical Trial.
5,515 results